Targeting Metabolic Bottlenecks in Lung Cancer

Volkan I Sayin; Sarah E LeBoeuf; Thales Papagiannakopoulos

doi:10.1016/j.trecan.2019.06.001

Targeting Metabolic Bottlenecks in Lung Cancer

Trends Cancer. 2019 Aug;5(8):457-459. doi: 10.1016/j.trecan.2019.06.001. Epub 2019 Jun 27.

Authors

Volkan I Sayin¹, Sarah E LeBoeuf², Thales Papagiannakopoulos³

Affiliations

¹ Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, SE-405 30 Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, SE-405 30 Gothenburg, Sweden.
² Department of Pathology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA; Perlmutter Cancer Center, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.
³ Department of Pathology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA; Perlmutter Cancer Center, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA. Electronic address: [email protected].

PMID: 31421901
DOI: 10.1016/j.trecan.2019.06.001

Abstract

Lung cancer remains one of the most genetically complex, aggressive, and lethal solid malignancies. Understanding how distinct lung cancer mutations give rise to altered nutrient requirements and promote immune evasion in the context of a heterogeneous lung tumor microenvironment is vital for the development of novel personalized therapeutic strategies.

Keywords: KEAP1; STK11/LKB1; immune evasion; lung cancer; metabolism; microenvironment.

Publication types

Review

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Adenocarcinoma of Lung / immunology
Adenocarcinoma of Lung / metabolism
Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Biomarkers, Tumor / antagonists & inhibitors*
Biomarkers, Tumor / genetics
Biosynthetic Pathways / drug effects
Biosynthetic Pathways / genetics
Genes, Tumor Suppressor
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / immunology
Lung Neoplasms / metabolism
Mutation
Oncogenes / genetics
Precision Medicine / methods
Precision Medicine / trends
Tumor Escape / drug effects
Tumor Escape / genetics
Tumor Microenvironment / drug effects
Tumor Microenvironment / genetics
Tumor Microenvironment / immunology

Substances

Antineoplastic Agents, Immunological
Biomarkers, Tumor